Bespoke research support on the companion diagnostics market
“We provide in-depth insight across leading healthcare diagnostic tests including in-vitro diagnostics (IVD) and molecular diagnostics for disease detection, key emerging trends, market sizing and forecasting”
The pandemic has had a positive impact on the companion diagnostics market due to the rising number of diagnostic procedures including polymerase chain reaction (PCR), next-generation sequencing (NGS), in situ hybridisation, immunohistochemistry, genome sequencing and molecular diagnostics
The growing significance of personalised medicine, the rising incidence of cancer and COVID-19 PCR testing, technological advancements and recent product launches will likely drive further growth in the global companion diagnostics market.
Most leading pharmaceutical and biotechnology companies including Thermo Fischer Scientific Inc., Illumina Inc., Bayer AG, F. Hoffmann-La Roche AG, Siemens Healthineers AG and Danaher Corporation Ltd are using companion diagnostics (CDx) kits and reagents to detect, for example, cancer, neurological disorders, heart disease, infectious diseases, respiratory and gastroenterological diseases and genetic disorders.
Our oncology subject-matter experts can provide assistance with research and insight in the field of oncology therapy including competitive intelligence, pipeline analysis and benchmarking, and market entry and due diligence.
BENEFITS AND IMPACT
Domain expertise across the life sciences and healthcare ecosystem, with specialised expertise in therapeutic areas such as oncology segments and rare diseases
Real-world expertise from solving challenges of 5 of the top 8 global pharmaceutical giants, meeting their strategic and business research needs
Actionable insights providing direct, meaningful action items for optimised decision making
Dedicated team that understands the specific needs of the life sciences sector, shares customised output and works towards building long-term client relationships
Flexible engagement models supporting changing requirements and dynamic market conditions to scale up or down, based on client requirement
Improved savings through operational cost savings, a dedicated team and automation
100% data confidentiality with industry-benchmarked SOC2 compliance
Cross-divisional support providing on-demand data analytics, financial services, deal tracking, commercial due diligence, M&A analysis and design and editorial support
Our offering
Oncology diagnostics research
Tap to flip
We help you manage the bulk of the research, freeing up your time to focus on more important areas
Recent trends and technologies
Competitive intelligence
Daily/weekly alerts tracking assets/competitors
KOL identification and primary research
Competitor profiling and benchmarking
Market assessment and sizing
Commercial and scientific conference coverage
Latest diagnostics products (kits, reagents, assays, services and software) launches
Updating internal databases
Literature searches and newsletters
Strategy research and due diligence projects
Tap to flip
Our extensive research capabilities can help you efficiently manage increased demand
Opportunity assessment and market attractiveness
Product launch strategies
Licensing and acquisition
Market entry and due diligence
Pricing and reimbursement strategies
Technology or partner scouting
Support with regulatory policies in healthcare
Tap to flip
We have been keeping abreast of changes in regulation and can help you create a master report along with daily/weekly alerts tracking recent changes
Regulatory approval in different countries
Regulatory barriers and strategies to overcome them
Pricing and reimbursement policies
Patient access programmes
Macroeconomic policies of different countries
Thank you for sharing your details
Share this on
